FOXA1 and prostate carcinoma: The results of our study provide evidence that FOXA1 staining level alone is not dramatically associated with risk of BCR after SRT and is therefore relatively unlikely to be of use in improving patient selection for SRT following recurrent prostate cancer after RP.